Karyopharm Competitors
| KPTI Stock | USD 6.52 0.11 1.66% |
Karyopharm Therapeutics vs Telomir Pharmaceuticals Correlation
Average diversification
The correlation between Karyopharm Therapeutics and TELO is 0.14 (i.e., Average diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Karyopharm Therapeutics and TELO in the same portfolio, assuming nothing else is changed.
Moving against Karyopharm Stock
| 0.69 | ACLX | Arcellx | PairCorr |
| 0.6 | RANI | Rani Therapeutics | PairCorr |
| 0.53 | CRBP | Corbus Pharmaceuticals | PairCorr |
| 0.51 | MBIO | Mustang Bio | PairCorr |
| 0.47 | APLT | Applied Therapeutics | PairCorr |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Karyopharm Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Karyopharm Therapeutics Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Karyopharm Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Karyopharm and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Karyopharm Therapeutics does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Karyopharm Stock performing well and Karyopharm Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Karyopharm Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| SNTI | 4.66 | (1.02) | 0.00 | (0.65) | 0.00 | 7.73 | 53.50 | |||
| BRNS | 3.10 | (0.77) | 0.00 | (1.50) | 0.00 | 5.71 | 24.01 | |||
| CVM | 4.80 | (0.54) | 0.00 | (0.26) | 0.00 | 10.19 | 30.91 | |||
| XFOR | 3.13 | 0.03 | 0.01 | 0.05 | 3.92 | 7.28 | 23.09 | |||
| ALGS | 4.53 | (0.13) | 0.00 | 0.59 | 0.00 | 10.16 | 28.43 | |||
| FGEN | 2.66 | (0.20) | 0.00 | 0.70 | 0.00 | 4.33 | 28.75 | |||
| INMB | 3.65 | (0.16) | 0.00 | 0.18 | 0.00 | 6.82 | 22.66 | |||
| MRSN | 7.16 | 3.30 | 0.84 | 0.63 | 2.27 | 7.25 | 210.61 | |||
| MDCX | 3.74 | (0.97) | 0.00 | (2.08) | 0.00 | 6.77 | 21.20 | |||
| TELO | 2.65 | (0.48) | 0.00 | (0.34) | 0.00 | 4.00 | 15.74 |
Cross Equities Net Income Analysis
Compare Karyopharm Therapeutics and related stocks such as Senti Biosciences, Barinthus Biotherapeutics, and CEL SCI Corp Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SNTI | (21.2 M) | (21.2 M) | (21.2 M) | (21.2 M) | (21.2 M) | (21.2 M) | (21.2 M) | (21.2 M) | (21.2 M) | (21.2 M) | (19.9 M) | (55.3 M) | (45.8 M) | (71.1 M) | (52.8 M) | (47.5 M) | (49.9 M) |
| BRNS | (20.7 M) | (20.7 M) | (20.7 M) | (20.7 M) | (20.7 M) | (20.7 M) | (20.7 M) | (20.7 M) | (20.7 M) | (20.7 M) | (17.7 M) | (50.9 M) | 5.3 M | (73.3 M) | (61.1 M) | (55 M) | (57.7 M) |
| CVM | (2.9 M) | (15.5 M) | (9.2 M) | (27.4 M) | (34.7 M) | (11.5 M) | (14.4 M) | (31.8 M) | (24.7 M) | (32.2 M) | (39.2 M) | (38.3 M) | (32.4 M) | (26.9 M) | (25.4 M) | (22.9 M) | (21.7 M) |
| XFOR | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (23 M) | (33.9 M) | (43 M) | (56.6 M) | (62.1 M) | (88.7 M) | (93.9 M) | (101.2 M) | (37.5 M) | (33.7 M) | (35.4 M) |
| ALGS | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (52.3 M) | (108.5 M) | (128.3 M) | (96 M) | (87.7 M) | (131.2 M) | (118.1 M) | (124 M) |
| INMB | (48.9 K) | (48.9 K) | (48.9 K) | (48.9 K) | (48.9 K) | (48.9 K) | (277 K) | (831 K) | (12.4 M) | (7.7 M) | (12.1 M) | (30.3 M) | (28.6 M) | (30 M) | (42.1 M) | (37.9 M) | (36 M) |
| MRSN | (16.4 M) | (16.4 M) | (16.4 M) | (16.4 M) | (16.4 M) | (16.4 M) | (13.7 M) | (38.7 M) | (64.3 M) | (28.2 M) | (88 M) | (170.1 M) | (204.2 M) | (171.7 M) | (69.2 M) | (62.3 M) | (65.4 M) |
| MDCX | (693.8 K) | (3.4 K) | (3.4 K) | (3.4 K) | (3.4 K) | (3.4 K) | (5.8 K) | (138.9 K) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (1.7 M) | (5.3 M) | (11.2 M) | (10 M) | (9.5 M) |
| TELO | (138.1 K) | (138.1 K) | (138.1 K) | (138.1 K) | (138.1 K) | (138.1 K) | (138.1 K) | (138.1 K) | (138.1 K) | (138.1 K) | (138.1 K) | (854.1 K) | (13.1 M) | (16.5 M) | (16.5 M) | (14.9 M) | (14.1 M) |
Karyopharm Therapeutics and related stocks such as Senti Biosciences, Barinthus Biotherapeutics, and CEL SCI Corp Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Karyopharm Therapeutics financial statement analysis. It represents the amount of money remaining after all of Karyopharm Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Karyopharm Therapeutics Competitive Analysis
The better you understand Karyopharm Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Karyopharm Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Karyopharm Therapeutics' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Karyopharm Therapeutics Competition Performance Charts
Five steps to successful analysis of Karyopharm Therapeutics Competition
Karyopharm Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Karyopharm Therapeutics in relation to its competition. Karyopharm Therapeutics' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Karyopharm Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Karyopharm Therapeutics' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Karyopharm Therapeutics, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Karyopharm Therapeutics position
In addition to having Karyopharm Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Investing Thematic Idea Now
Investing
Companies involved in money management and investment banking services. The Investing theme has 38 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Investing Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Karyopharm Therapeutics Correlation with its peers. For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is there potential for Biotechnology market expansion? Will Karyopharm introduce new products? Factors like these will boost the valuation of Karyopharm Therapeutics. Expected growth trajectory for Karyopharm significantly influences the price investors are willing to assign. Understanding fair value requires weighing current performance against future potential. All the valuation information about Karyopharm Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (14.70) | Revenue Per Share | Quarterly Revenue Growth 0.136 | Return On Assets | Return On Equity |
The market value of Karyopharm Therapeutics is measured differently than its book value, which is the value of Karyopharm that is recorded on the company's balance sheet. Investors also form their own opinion of Karyopharm Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Karyopharm Therapeutics' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Karyopharm Therapeutics' market value can be influenced by many factors that don't directly affect Karyopharm Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Karyopharm Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Karyopharm Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Karyopharm Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.